Completed PHASE4 INTERVENTIONAL 2-arm NCT02772640

Effectiveness of Treatment of Hypercholesterolemia With Rosuvastatin and Ezetimibe (ROSEZE)

The Impact of the Time of Drug Administration on the Effectiveness of Combined Treatment of Hypercholesterolemia With ROSuvastatin and EZEtimibe (ROSEZE) - A Single-center, Crossover, Open-label Study

Sponsor: Collegium Medicum w Bydgoszczy

Conditions Hypercholesterolemia

Interventions Rosuvastatin and Ezetimibe morning or evening administration

Updated 7 times since 2017 Last updated: Jan 29, 2021 Started: Mar 31, 2016 Primary completion: Jan 31, 2019 Completion: May 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Hypercholesterolemia, this trial is completed. The trial is conducted by Collegium Medicum w Bydgoszczy and has accumulated 7 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Mar 2021 — Jul 2024 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Jan 2021 — Mar 2021 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE4

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Collegium Medicum w Bydgoszczy

Data source: Collegium Medicum w Bydgoszczy

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bydgoszcz, Poland